The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
